WallStSmart

GE HealthCare Technologies Inc. (GEHC)vsGlaukos Corp (GKOS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 3965% more annual revenue ($20.63B vs $507.44M). GEHC leads profitability with a 10.1% profit margin vs -37.0%. GKOS appears more attractively valued with a PEG of 1.64. GEHC earns a higher WallStSmart Score of 60/100 (C+).

GEHC

Buy

60

out of 100

Grade: C+

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.3
Piotroski: 2/9Altman Z: 1.34

GKOS

Hold

44

out of 100

Grade: D

Growth: 9.3Profit: 2.0Value: 6.7Quality: 5.8
Piotroski: 3/9Altman Z: 1.49
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

GEHCSignificantly Overvalued (-156.0%)

Margin of Safety

-156.0%

Fair Value

$30.94

Current Price

$72.20

$41.26 premium

UndervaluedFair: $30.94Overvalued

Intrinsic value data unavailable for GKOS.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GEHC2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

GKOS1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
35.7%10/10

Revenue surging 35.7% year-over-year

Areas to Watch

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-17.7%2/10

Earnings declined 17.7%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

GKOS4 concerns · Avg: 3.3/10
PEG RatioValuation
1.644/10

Expensive relative to growth rate

Price/BookValuation
9.6x4/10

Trading at 9.6x book value

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-26.4%2/10

ROE of -26.4% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : GEHC

The strongest argument for GEHC centers on Return on Equity, P/E Ratio.

Bull Case : GKOS

The strongest argument for GKOS centers on Revenue Growth. Revenue growth of 35.7% demonstrates continued momentum.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Bear Case : GKOS

The primary concerns for GKOS are PEG Ratio, Price/Book, Piotroski F-Score.

Key Dynamics to Monitor

GEHC profiles as a value stock while GKOS is a hypergrowth play — different risk/reward profiles.

GEHC carries more volatility with a beta of 1.18 — expect wider price swings.

GKOS is growing revenue faster at 35.7% — sustainability is the question.

GEHC generates stronger free cash flow (917M), providing more financial flexibility.

Bottom Line

GEHC scores higher overall (60/100 vs 44/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Glaukos Corp

HEALTHCARE · MEDICAL DEVICES · USA

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, is focused on developing new therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in San Clemente, California.

Want to dig deeper into these stocks?